Wang Kang-Ling, Chu Pao-Hsien, Lee Cheng-Han, Pai Pei-Ying, Lin Pao-Yen, Shyu Kou-Gi, Chang Wei-Tien, Chiu Kuan-Ming, Huang Chien-Lung, Lee Chung-Yi, Lin Yen-Hung, Wang Chun-Chieh, Yen Hsueh-Wei, Yin Wei-Hsian, Yeh Hung-I, Chiang Chern-En, Lin Shing-Jong, Yeh San-Jou
General Clinical Research Center, Taipei Veterans General Hospital; School of Medicine, National Yang-Ming University;
Division of Cardiology, Department of Internal Medicine, Heart Failure Center, Healthcare Center, Chang Gung Memorial Hospital; College of Medicine, Chang Gung University;
Acta Cardiol Sin. 2016 Jan;32(1):1-22. doi: 10.6515/acs20151228a.
Deep vein thrombosis (DVT) is a potentially catastrophic condition because thrombosis, left untreated, can result in detrimental pulmonary embolism. Yet in the absence of thrombosis, anticoagulation increases the risk of bleeding. In the existing literature, knowledge about the epidemiology of DVT is primarily based on investigations among Caucasian populations. There has been little information available about the epidemiology of DVT in Taiwan, and it is generally believed that DVT is less common in Asian patients than in Caucasian patients. However, DVT is a multifactorial disease that represents the interaction between genetic and environmental factors, and the majority of patients with incident DVT have either inherited thrombophilia or acquired risk factors. Furthermore, DVT is often overlooked. Although symptomatic DVT commonly presents with lower extremity pain, swelling and tenderness, diagnosing DVT is a clinical challenge for physicians. Such a diagnosis of DVT requires a timely systematic assessment, including the use of the Wells score and a D-dimer test to exclude low-risk patients, and imaging modalities to confirm DVT. Compression ultrasound with high sensitivity and specificity is the front-line imaging modality in the diagnostic process for patients with suspected DVT in addition to conventional invasive contrast venography. Most patients require anticoagulation therapy, which typically consists of parenteral heparin bridged to a vitamin K antagonist, with variable duration. The development of non-vitamin K oral anticoagulants has revolutionized the landscape of venous thromboembolism treatment, with 4 agents available,including rivaroxaban, dabigatran, apixaban, and edoxaban. Presently, all 4 drugs have finished their large phase III clinical trial programs and come to the clinical uses in North America and Europe. It is encouraging to note that the published data to date regarding Asian patients indicates that such new therapies are safe and efficacious. Ultimately, our efforts to improve outcomes in patients with DVT rely on the awareness in the scientific and medical community regarding the importance of DVT.
Combination therapy; Hypertension; α1-blocker.
深静脉血栓形成(DVT)是一种潜在的灾难性疾病,因为血栓若不治疗,可能导致有害的肺栓塞。然而,在没有血栓形成的情况下,抗凝会增加出血风险。在现有文献中,关于DVT流行病学的知识主要基于对白种人群的调查。关于台湾DVT流行病学的信息很少,人们普遍认为亚洲患者中DVT的发生率低于白种患者。然而,DVT是一种多因素疾病,代表遗传和环境因素之间的相互作用,大多数新发DVT患者要么有遗传性血栓形成倾向,要么有获得性危险因素。此外,DVT常常被忽视。虽然有症状的DVT通常表现为下肢疼痛、肿胀和压痛,但对医生来说,诊断DVT是一项临床挑战。DVT的诊断需要及时进行系统评估,包括使用Wells评分和D - 二聚体检测以排除低风险患者,以及使用影像学检查来确诊DVT。除了传统的有创静脉造影外,具有高灵敏度和特异性的加压超声是疑似DVT患者诊断过程中的一线影像学检查方法。大多数患者需要抗凝治疗,通常包括静脉注射肝素桥接维生素K拮抗剂,疗程不一。非维生素K口服抗凝剂的出现彻底改变了静脉血栓栓塞症的治疗格局,现有4种药物,包括利伐沙班、达比加群、阿哌沙班和依度沙班。目前,这4种药物均已完成大型III期临床试验项目,并在北美和欧洲投入临床使用。令人鼓舞的是,迄今为止公布的关于亚洲患者的数据表明,这些新疗法是安全有效的。最终,我们改善DVT患者治疗效果的努力依赖于科学界和医学界对DVT重要性的认识。
联合治疗;高血压;α1阻滞剂。